Table 1.
Baseline characteristics of GBM cohort stratified by Dex administration during TTFields treatment.
| Numbers | Dex =10 | no Dex =16 | p-value |
|---|---|---|---|
| Sex | |||
| Male (n) | 6 (60%) | 12 (75%) | n.s. |
| Female (n) | 4 (40%) | 4 (25%) | n.s. |
| Median age | |||
| Years | 55 (23-75) | 50 (27-68) | n.s. |
| MGMT status | |||
| Methylated | 5 (50%) | 7 (44%) | n.s. |
| Unmethylated | 5 (50%) | 9 (56%) | n.s. |
| IDH-1 status | |||
| Wildtype | 9 (90%) | 16 (100%) | n.s. |
| Mutated | 1 (10%) | 0 (0%) | n.s. |
| P 53 | |||
| Wildtype | 6 (60%) | 6 (38%) | n.s. |
| Mutated | 4 (40%) | 10 (62%) | n.s. |
| Survival | |||
| Progression-free survival in months (range) | 9 (5-28) | 11 (5-39) | n.s. |
| Overall survival in months (range) | 15 (8-32) | 18 (7-39) | n.s. |
| Median TTFields application in days | 177 (21-260) | 92 (59-409) | n.s. |
| Median Days from operation to TTFields | 163.5 (46.9) | 175.5 (64.3) | n.s. |
ns, non significant.